Table 1 Baseline characteristics and organ involvement.

From: A validated composite organ and hematologic response model for early assessment of treatment outcomes in light chain amyloidosis

 

Mayo cohort N = 473 N (%) or Median (IQR)

Pavia cohort, N = 575 N (%) or Median (IQR)

Median age, years

63 (56–69)

64 (56–70)

Sex, males

309 (65)

335 (58)

Involved light chain, lambda

354/467 (78)

450/575 (78)

Median M-protein (g/dL)

0 (0–0.6)

0.8 (0–1.5)

Median dFLC (mg/dL)

19 (8–55)

19 (9–52)

dFLC <5 mg/dL

63 (13)

39 (7)

Bone marrow plasma cells (%)

10 (5–12)

11 (7–20)

NT-Pro BNP (pg/mL)

1625 (327–4296)

2215 (704–5578)

Troponin-T (ng/mL)

0.02 (0.01–0.05)

Not available

Troponin-I (ng/mL)

Not available

0.05 (0.02–0.13)

Median 24 h urine protein (mg)

2629 (375–7008)

2561 (392–6590)

Median GFR (ml/min/1.73 m2 BSA)

65 (48–82)

69 (49–87)

Median alkaline phosphatase (U/L)

86 (69–118)

149 (88–217)

Mayo 2012 stage 1/2/3/4

125/123/115/93 (27/27/25/20) (N = 456)

109/159/151/111 (20/30/28/22) (N = 530)

Mayo 2004 stage 1/2/3a/3b

107/205/108/37 (23/45/24/8) (N = 457)

78/276/107/69 (15/52/20/13) (N = 530)

Renal stage 1/2/3 (%)

229/183/53 (49/39/11), N = 465

285/213/68 (50/37/13) N = 566

iFISH—t (11; 14)

172/325 (53)

Not available

iFISH—trisomy/tetrasomy

67/326 (21)

Not available

Organ involvement

  

Heart

332 (70)

454 (79)

Kidney

330 (70)

399 (69)

Liver

66 (14)

64 (11)

Gastrointestinal system

101 (21)

13 (2)

Autonomic nervous system

47 (10)

61 (10)

Major organ involveda

  

One major organ involved

255 (54)

269 (47)

Two major organs involved

181 (37)

268 (46)

Three major organs involved

37 (8)

38 (7)

More than one major organ involved

218 (46)

306 (53)

  1. BSA body surface area, dFLC difference in involved and uninvolved free light chains, GFR Glomerular filtration rate, IQR interquartile, iFISH interphase fluorescence in situ hybridization, M-protein monoclonal protein.
  2. aMajor organs: heart, kidney, and liver.